Suppr超能文献

运用三黄汤改善炎症状态以减少乳腺癌患者术后渗出液:一项前瞻性临床试验

Reducing postsurgical exudate in breast cancer patients by using San Huang decoction to ameliorate inflammatory status: a prospective clinical trial.

作者信息

Zhu Z Y, Xue J X, Yu L X, Bian W H, Zhang Y F, Sohn K C, Shin I H, Yao C

机构信息

Department of Breast Disease, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing, P.R.C.

Hospital of Catholic University of Daegu, Daegu, Republic of Korea.

出版信息

Curr Oncol. 2018 Dec;25(6):e507-e515. doi: 10.3747/co.25.4108. Epub 2018 Dec 1.

Abstract

BACKGROUND

Reducing inflammatory factors in wound exudate is a promising treatment approach for healing wounds in postsurgical breast cancer patients. Traditional Chinese Medicine (tcm) treatments have been shown to be beneficial and safe for optimal regulation of oxidative stress during the postoperative period. In the present clinical trial, we evaluated the effectiveness of a promising Chinese herbal formula, San Huang decoction [shd (Radix astragali, Radix et rhizoma rhei, and Rhizoma curcuma longa, 3:1:1; supplemental Table 1)], on wound inflammatory response after mastectomy.

METHODS

The study randomized 30 patients with breast cancer who fulfilled the inclusion and exclusion criteria to either a treatment ( = 15) or a control group ( = 15). Patients in the treatment group received liquid shd, taken twice daily with or without food. Treatment was given for 1 day before surgery and for 7 days postoperatively. Participants in the control group received a placebo on the same schedule as the treatment group. Outcomes measured in every subject included clinical tcm and wound inflammation symptom scores, daily and total amounts of drainage fluid, and levels of inflammatory factors in the exudate [tumour necrosis factor α (tnf-α), interleukins 6 (il-6), 8 (il-8), and 2R (il-2R), human C-reactive protein (crp)] at 2 hours and on days 1, 3, and 7 postoperatively.

RESULTS

The total amount of drainage fluid over 7 days was significantly lower in the treatment group (572.20 ± 93.95 mL) than in the control group (700.40 ± 107.38 mL). The tcm symptom score was also lower in treatment group (day 7: 1.87 ± 0.83 vs. 4.80 ± 3.61, = 0.049), as was the inflammatory symptom score (day 7: 0.67 ± 0.72 vs. 3.67 ± 2.50, = 0.001). Levels of tnf-α, il-6, il-8, il-2R, and crp in drainage fluid were significantly lower with shd treatment.

CONCLUSIONS

Perioperative treatment with shd effectively lessened postoperative exudate and ameliorated inflammatory symptoms in patients who underwent surgery for breast cancer.

摘要

背景

降低伤口渗出液中的炎症因子是治疗乳腺癌术后伤口愈合的一种有前景的方法。中药治疗已被证明对术后氧化应激的最佳调节有益且安全。在本临床试验中,我们评估了一种有前景的中药配方三黄汤[三黄汤(黄芪、大黄、姜黄,3:1:1;补充表1)]对乳房切除术后伤口炎症反应的有效性。

方法

该研究将30例符合纳入和排除标准的乳腺癌患者随机分为治疗组(n = 15)和对照组(n = 15)。治疗组患者接受三黄汤液剂,每天服用两次,可与食物同服或不同服。在手术前1天和术后7天进行治疗。对照组参与者按照与治疗组相同的时间表接受安慰剂。测量每个受试者的结果包括中医临床和伤口炎症症状评分、引流液的每日量和总量,以及术后2小时、第1天、第3天和第7天渗出液中炎症因子的水平[肿瘤坏死因子α(TNF-α)、白细胞介素6(IL-6)、8(IL-8)和2R(IL-2R)、人C反应蛋白(CRP)]。

结果

治疗组7天内引流液总量(572.20±93.95 mL)明显低于对照组(700.40±107.38 mL)。治疗组的中医症状评分也较低(第7天:1.87±0.83 vs. 4.80±3.61,P = 0.049),炎症症状评分也是如此(第7天:0.67±0.72 vs. 3.67±2.50,P = 0.001)。三黄汤治疗后,引流液中TNF-α、IL-6、IL-8、IL-2R和CRP的水平明显降低。

结论

围手术期使用三黄汤治疗可有效减少乳腺癌手术患者的术后渗出液并改善炎症症状。

相似文献

2
Antistress Effects of Decoction on Restraint-Stressed Mice Revealed by H NMR-Based Metabolomics and Biochemistry Analysis.
Oxid Med Cell Longev. 2019 Apr 16;2019:5897675. doi: 10.1155/2019/5897675. eCollection 2019.
5
Diabetes is an inflammatory disease: evidence from traditional Chinese medicines.
Diabetes Obes Metab. 2011 Apr;13(4):289-301. doi: 10.1111/j.1463-1326.2010.01336.x.
8
San Huang Decoction downregulates Aurora kinase A to inhibit breast cancer cell growth and enhance chemosenstivity to anti-tumor drugs.
Pathol Res Pract. 2016 Aug;212(8):696-703. doi: 10.1016/j.prp.2016.05.004. Epub 2016 May 18.

引用本文的文献

1
Sophoridine inhibits proliferation and migration by targeting PIM1 in breast cancer.
Pharm Biol. 2025 Dec;63(1):503-523. doi: 10.1080/13880209.2025.2537123. Epub 2025 Jul 24.
3
Clinical trial-identified inflammatory biomarkers in breast and pancreatic cancers.
Front Endocrinol (Lausanne). 2023 Apr 27;14:1106520. doi: 10.3389/fendo.2023.1106520. eCollection 2023.
4
Role of Turmeric and Curcumin in Prevention and Treatment of Chronic Diseases: Lessons Learned from Clinical Trials.
ACS Pharmacol Transl Sci. 2023 Mar 6;6(4):447-518. doi: 10.1021/acsptsci.2c00012. eCollection 2023 Apr 14.
5
Wound fluid sampling methods for proteomic studies: A scoping review.
Wound Repair Regen. 2022 May;30(3):317-333. doi: 10.1111/wrr.13009. Epub 2022 Apr 5.
6
Sanhuang Decoction Controls Tumor Microenvironment by Ameliorating Chronic Stress in Breast Cancer: A Report of Ninety Cases.
Front Oncol. 2021 Aug 17;11:677939. doi: 10.3389/fonc.2021.677939. eCollection 2021.

本文引用的文献

1
Reply: Late Surgical-Site Infection in Immediate Implant-Based Breast Reconstruction.
Plast Reconstr Surg. 2017 Nov;140(5):750e. doi: 10.1097/PRS.0000000000003778.
2
NCCN Guidelines Insights: Breast Cancer, Version 1.2017.
J Natl Compr Canc Netw. 2017 Apr;15(4):433-451. doi: 10.6004/jnccn.2017.0044.
3
Decision aids for people facing health treatment or screening decisions.
Cochrane Database Syst Rev. 2017 Apr 12;4(4):CD001431. doi: 10.1002/14651858.CD001431.pub5.
4
Breast cancer subtype distribution is different in normal weight, overweight, and obese women.
Breast Cancer Res Treat. 2017 Jun;163(2):375-381. doi: 10.1007/s10549-017-4192-x. Epub 2017 Mar 14.
5
San Huang Decoction downregulates Aurora kinase A to inhibit breast cancer cell growth and enhance chemosenstivity to anti-tumor drugs.
Pathol Res Pract. 2016 Aug;212(8):696-703. doi: 10.1016/j.prp.2016.05.004. Epub 2016 May 18.
10
Introducing the SKIN score: a validated scoring system to assess severity of mastectomy skin flap necrosis.
Ann Surg Oncol. 2015 Sep;22(9):2925-32. doi: 10.1245/s10434-015-4409-3. Epub 2015 Jan 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验